RE:RE:Bonne Chance Agree that sooner or later Alvira will need to give details on the price model with ascend so analysts can cover them (if they ever get there). Ascend is a small out for (40ish people listed on LinkedIn) around 13 witthin sales so it will very much depend on how incentivized from a pricing split ascend and their sellers are to push VMS as well how much effort they will put behind it. Ventripoint has one sales manger in the USA and one demo clinical person. No sign they will ramp this up so there sales team is tiny. Execution will be everything and getting away from device sales is needed. A year into Alvira's stint and two sales to show and no mention of any pos outstanding last investor call (she said she would not comment on advanced pos - question I asked). A lot of unanswered questions / details to play out.
I still have some confidence that they 1) are slowly getting on track with a pivot to ascend (tiny vendor / partner compared to GE) which seems to have a good reach in the USA and can move more quickly than GE HC. 2) recent Ollie Hinkle Heart foundation partnership. IHHF budget isn't large $1.5m a year and majority spent direct to patients and their families so I do not expect them to buy more than a handful of vms units if that but the intros to hospitals is needed as the USA sales manager imo needs to go. 3) capital being a manged ok but I expect a raise in Q1 or Q2. 4) 4.0 eliminates the pain point of the user placing the points which should help make VMS easier to use
time will tell. Would like to get to my breakeven so o can start to off load some risk.